The Caithness Business Index has posted the following article:

Mhra Approves Glp -1 Receptor Agonist Semaglutide To Reduce Risk Of Serious Heart Problems In Obese Or Overweight Adults

[IMG][/IMG] Semaglutide is the first weight loss drug approved in the UK as a preventative treatment for those with established cardiovascular disease. The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 July 2024, approved a new indication for semaglutide (Wegovy) to reduce the risk of overweight and obese adults suffering serious heart problems or strokes. [Read Full Article]